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Abstract
The Toll-like receptor (TLR) 3 plays a critical role in mammalian innate immune response against viral attacks by recognizing
double-stranded RNA (dsRNA) or its synthetic analog polyinosinic-polycytidylic acid (poly (I:C)). This leads to the activation
of MAP kinases and NF-kB which results in the induction of type I interferons and proinflammatory cytokines to combat the
viral infection. To understand the complex interplay of the various intracellular signaling molecules in the regulation of NF-
kB and MAP kinases, we developed a computational TLR3 model based upon perturbation-response approach. We curated
literature and databases to determine the TLR3 signaling topology specifically for murine macrophages. For initial model
creation, we used wildtype temporal activation profiles of MAP kinases and NF-kB and, for model testing, used TRAF6 KO
and TRADD KO data. From dynamic simulations we predict i) the existence of missing intermediary steps between
extracellular poly (I:C) stimulation and intracellular TLR3 binding, and ii) the presence of a novel pathway which is essential
for JNK and p38, but not NF-kB, activation. Our work shows activation dynamics of signaling molecules can be used in
conjunction with perturbation-response models to decipher novel signaling features of complicated immune pathways.
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Introduction
Toll-Like Receptors (TLRs) play a major role in innate
immunity, the first line of mammalian defense against invading
pathogens and crucial for antigen-specific acquired immunity
development [1,2]. Upon the recognition of pathogen-associated
molecular patterns (PAMPs), such as bacterial lipopolysaccharide
(LPS) and viral dsRNA, the 13 currently known TLRs trigger
predominantly the activation of MAP kinases and several key
transcription factors including nuclear factor-kB (NF-kB), activa-
tor protein (AP)-1 and interferon regulatory factor (IRF)- 3 and 7.
This results in the induction of numerous proinflammatory
cytokines and type I interferons [3,4,5]. The dysregulation of
TLR signaling, therefore, has been attributed to the pathogenesis
of major pro-inflammatory illnesses such as the autoimmune
diseases [6,7].
TLR3, one of the 4 known intracellular members of TLR
family, recognizes dsRNA and poly (I:C) [3,5,8] triggers an innate
response independent of the adaptor protein Myeloid Differenti-
ation factor 88 (MyD88), which is required for all other TLRs
[8,9]. The specificity of TLR3 response is possibly due to the
occurrence of an alanine residue in a critical region of its
cytoplasmic domain unlike the proline residue utilized by MyD88
found in other TLRs [5]. Thus, TLR3 initiates its response
depending only on the adaptor protein TIR domain-containing
adapter-including interferon-b (TRIF) [2,10]. The recruitment of
TRIF mediates the signaling process through the activation of key
transcription factors NF-kB, AP-1, IRF-3 and 7 [3,5,8]. Although
the signaling molecules and their cascades have been broadly
investigated, the dynamic outcome of signal transduction between
wildtype and genetic mutations still remains poorly understood.
Here, we began the investigation of TLR3 pathway by
literature/database curation of the signaling topology in murine
macrophages. Next, we analyzed the temporal experimental data
of wildtype, TNF Receptor Associated Factor (TRAF)-6 and
NFRSF1A-associated via death domain (TRADD)-deficient mu-
rine macrophages with poly (I:C) stimulation [11–12] by
developing a computational TLR3 model based on perturba-
tion-response approach. This approach does not require the
detailed reaction kinetics of each reaction in the signaling topology
(as in bottom-up approaches), but rather, considers the activation
of signaling molecules as linear response events [13]. Similar
modeling approaches have been previously used to infer important
biological network features; inferring feedback control of IKK
activity in tumour-necrosis factor (TNF) stimulation [14],
uncovering switching behaviour of MAPK signaling between
epidermal growth factor (EGF) and neuronal growth factor (NGF)
stimuli [15], detecting connectivities of reaction molecules [16],
predicting missing molecules in TLR4 signaling [17] and signaling
flux redistribution (SFR) at pathway junctions [18].
Our TLR3 model simulations were compared with temporal
experimental data of NF-kB, JNK and p38 in three experimental
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4661conditions; wildtype, TRAF6-deficient and TRADD-deficient
macrophages. Collectively, the results suggest i) the existence of
novel intermediary steps (e.g. missing cellular processes, proteins
or phosphorylation states) between extracellular poly (I:C)
stimulation and intracellular TLR3 binding, and ii) the presence
of a novel pathway which is essential for JNK and p38 activation.
Results and Discussion
Determination of the TLR3 signaling topology in
macrophages
TLR3 is expressed in several cell types including macrophages,
murine embryonic fibroblasts (MEFs) and dendritic cells (DCs),
however, it was not found in B Cells, T Cells and NK cells
[8,19,20,21,22]. Moreover, the experimental observations of
TLR3 signaling under various genetic knock-outs show contro-
versial roles of certain molecules in different cell types. For
instance, Gohda et al. [11] showed that TRAF6 is dispensable for
TLR3 induced NF-kB in poly (I:C) stimulated macrophages, while
Jiang et al. [23] showed the requirement of TRAF6 to NF-kB
activation in MEFs. Also, for NF-kB and MAP kinases activation,
TRADD is not critical in macrophages, whereas, it is important
for MEFs [12,24]. These data indicate that there is no common
topology for TLR3 signaling and, therefore, we cannot combine
data obtained from different cell types to create unified TLR3
signaling topology. Instead, independent cell type analysis should
be performed.
Here, we investigate the signaling topology for murine
macrophages only. It is known that TRIF interacts with TLR3
at the TIR domain and TRAF6 binds to the N-terminal of TRIF
[8,11,25]. However, we found, in murine macrophages, the role of
TRAF6 in TLR3 signaling is dispensable [11]; the temporal
experimental profiles of MAP kinases (JNK and p38) and NF-kB
activation to poly (I:C) stimulation in TRAF6 KO were only
slightly reduced compared with wildtype levels (Figure 1A–C WT
and TRAF6 KO).
Recently, TRADD has been shown to be involved in the TLR3
signaling [11,24,26]. TRADD-deficient macrophages showed
downregulation of MAP Kinases and a slight upregulation of
NF-kB activation (Figure 1A–C TRADD KO) [11]. RIP1, which
binds to TRIF at C-terminal (RHIM domain), interacted with
TRADD through death domain (DD) suggesting TRADD’s
possible involvement in RIP1 ubiquitination [12]. Since RIP1 is
required for TRIF-dependent signaling in response to poly (I:C)
stimulation [27], TRADD is likely involved in NF-kB activation
via RIP1. Putting together, we created a macrophage TLR3
signaling topology (Figure 2A).
The prediction of missing intermediary cellular processes
in poly (I:C) stimulated macrophages
So far, we have built the signaling topology for TLR3 pathways
in macrophages. Next, to understand the complex dynamic
interplay of the various intracellular signaling molecules in the
regulation of NF-kB, JNK and p38 in poly (I:C) stimulation, we
developed a computational model of the TLR3 signaling (see
Materials and Methods). Each signaling response (i.e., the rate of
activation of each signaling molecule) in the model is represented
by ddX
dt ~JdX, where dX is relative activated concentration of
signaling molecules and the parameters (elements of J) are chosen
to fit the semi-quantitative experimental profiles (e.g, western
blots, EMSA, etc.) of NF-kB, JNK and p38 of wildtype
macrophages stimulated with poly (I:C) (Figure 1A–C WT). As
mentioned earlier, TRAF6 KO does not noticeably affect NF-kB,
JNK or p38 activation compared to wildtype (Figure 1A–C).
Hence, in the model, we used a low parameter value between
TRIF and TRAF6 to limit the response flux propagation through
TRAF6 such that the removal of TRAF6 in the model will only
slightly affect its downstream reactions (see Materials and Methods
for details).
We, next, simulated activation of NF-kB, JNK and p38 in
wildtype. Our results show the time to reach peak values were 15–
Figure 1. NF-kB and JNK experimental activation profiles. A), B)
and C) show experimental activation profiles of NF-kB, JNK and p38,
respectively in (WT) (black), TRAF6 KO (green), TRADD KO (orange)
obtained from [11,12]. The activation levels were quantified from the
western blots using ImageJ [http://rsbweb.nih.gov/ij/]. The x-axis
represents the time in minutes and the y-axis represents the relative
activation profile. Note: As TRADD KO data is unavailable at 10 min
(earliest at 15 min), we could not observe delayed activation of as
noted for WT and TRAF6 KO. Therefore, we used dotted line to connect
0 min and 15 min time points.
doi:10.1371/journal.pone.0004661.g001
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this model could not explain the delayed experimental activation
of NF-kB, JNK and p38. We can consider time delay processes of
signaling events are due to missing molecules/complex formation
or spatial movement of molecules [13]. The deterministic kinetic
evolution equation used in our model, non-linear F in general
(Eq.1, Materials and Methods), can include such information by
setting total derivative of time to partial derivative in time and
space. In other words, Jacobian matrix J can contain temporal and
spatial information of the network process. Since we are not
performing spatial simulation, time delay response can be lumped
as missing molecules/processes in the network. For example, using
a TLR4 model, we previously predicted the delayed activation of
TRIF-dependent pathways by using a number of additional
response reactions representing missing signaling features (mole-
cules/processes, spatial movements or complex formation) in the
original network [17]. Our result was later substantiated by
McGettick et al., 2006 [28] who demonstrated two novel signaling
molecules (PKCe and TRAM) act upstream of TRIF and,
recently, by Kagan et al., 2008 [29] who discovered that the
internalization of TLR4 into the endosome is required prior to
TRIF-dependent pathway activation. Thus, the delayed activation
of NF-kB and MAP Kinases in poly (I:C) stimulation could also be
due to missing molecules or cellular processes.
To investigate and locate the likely position of the necessary
missing intermediary steps in the TLR3 pathway predicted by the
Figure 2. Analysis of TLR3 pathway in macrophages. A) Schematic representation of the determined TLR3 pathway topology in macrophages.
dsRNA or poly (I:C) stimulated TLR3 triggers TRIF dependant response by the recruitment of TRIF to the cytoplasmic domain of the receptor which
then allows RIP1, TRAF6, TBK1 and TRAF3 to bind with TRIF. This results in the activation of MAP kinases (MKK1/2, MKK3/6 and MKK4/7) and IkB
kinase complex; MKK1/2, MKK3/6 and MKK4/7 activate ERK, JNK and p38, respectively and IkBa degradation releases NF-kB. TBK1 phosphorylates IRF-
3 and 7. ERK, JNK and p38 translocate to the nucleus and activate the transcription factor AP-1, and NF-kB, IRF-3 and IRF-7 translocate to the nucleus.
AP-1 and NF-kB bind to the promoter regions of cytokine genes such as Tnf and Il6 while IRF-3, IRF-7 together with NF-kB bind to the promoter
region of chemokine genes such as Cxcl10 and Ccl5 and induce their transcription. Protein-protein interactions between molecules at the two
signaling branches analyzed are highlighted in brown and blue. The dotted lines indicate weak activation (see maintext). B), C) and D) show
simulations of NF-kB, JNK and p38 activation, respectively, in wildtype (WT). The x-axis represents the time in minutes and the y-axis represents the
relative activation profile.
doi:10.1371/journal.pone.0004661.g002
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PLoS ONE | www.plosone.org 3 March 2009 | Volume 4 | Issue 3 | e4661model, we further surveyed the literature. TRIF directly bind to the
TIRdomainofTLR3 anddoesnotrequire TRAMforitsactivation
[30]. Thus, it is unlikely that missing intermediary steps exist
between TLR3 and TRIF. Furthermore, TLR3 KO and TRIFKO
both showed similar response; abolished activation of NF-kBa n d
MAP Kinases [30]. These data led us to hypothesize the missing
intermediary steps (e.g. signaling molecules or processes) are
upstream of TLR3 and we updated our model to begin simulation
not from TLR3, but rather from poly (I:C) downwards (Figure 3A).
We alsorepresented each new uncharacterized molecule/process as
a signaling intermediate in our model.
To obtain the delayed activation of NF-kB and MAP kinases in
accordance with experimental data of wildtype, that is, null
activation till 10 min, peak values around 30 min and reduced
activation after 60 min for all molecules (Figure 1A–C), we were
required to add three intermediary steps (signaling intermediates)
(Figure 3B–D WT). Having less or more intermediary steps
resulted in peak value reaching faster or slower than experimental
peak, respectively (data not shown).
While preparing this manuscript, Liu et al. demonstrated that
TLR3-ectodomains dimerizes before signal propagation [31]. Our
prediction of novel intermediary steps in upstream of TLR3
activation indicates that TLR3-ectodomains dimerization could be
one of the missing intermediary steps. The other intermediary
steps could indicate the endocytosis of poly (I:C) and its subsequent
transport mechanisms to be recognized by TLR3.
The existence of missing pathway for MAP Kinases
activation in poly (I:C) stimulation
To further test the predictive capability of our model, we
simulated TRAF6 KO and TRADD KO (see Materials and
Figure 3. Prediction of missing steps prior to poly (I:C)/TLR3 binding. A) Schematic representation of TLR3 model after adding three
signaling intermediates upstream of TLR3 representing uncharacterized cellular processes (blue) and TLR3-ectodomain dimerization (red dotted) (see
maintext). Note: from our model, it is not possible to equate the three intermediary steps to represent exactly three actual biological events, since
spatial transport processes might be one of candidates for the time delay. B), C) and D) show simulations of NF-kB, JNK and p38 activation,
respectively, in the wildtype (WT) (black), TRAF6 KO (green), TRADD KO (orange). The x-axis represents the time in minutes and the y-axis represents
the relative activation profile.
doi:10.1371/journal.pone.0004661.g003
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successfully simulate the activation of NF-kB, JNK and p38 in all
three conditions: wildtype, TRAF6 KO and TRADD KO. To
create KO condition from wildtype model, we set the reactions of
the KO molecule null, while all other model parameters retain
their original wildtype values.
The TRAF6 KO simulations matched the experimental data,
i.e., the removal of TRAF6 only slightly downregulated NF-kB,
JNK and p38 activation (Figure 3B–D TRAF6 KO). For TRADD
KO, NF-kB activation was slightly increased in experiments
(Figure 1A). This result was recapitulated by our model which
suggests the enhancement of NF-kB activation in TRADD KO is
due to signaling flux redistribution [18] (Figure 3B TRADD KO).
However, in contrasts to experimental results, which showed only
a small downregulation, simulations of JNK and p38 showed
almost abolished activation (Figure 3C–D TRADD KO). Thus,
our simulation failure suggests, in actual cells, a novel pathway
might exist that compensate the loss of MAP Kinases activation in
TRADD KO.
Macrophages with TRIF mutation treated with poly (I:C)
showed abolishment of MAP kinase ERK activation [32] and all
MAP kinases showed similar kinetics in wildtype and TRAF6 KO
[11]. Thus, we added a pathway from TRIF to MAP kinases into
our model (Figure 4A and Table 1) and adjusted the parameter
values between TRIF to RIP1, TRADD and the novel pathway to
fit wildtype NF-kB, JNK and p38 activation. We re-performed the
simulations of TRAF6 KO and TRADD KO. The final model
simulations matched experimental outcome for all three conditions
(Figure 4B–D).
To investigate other possible pathways for JNK and p38
activation in poly (I:C) stimulation, reports indicate two other
receptors known to recognize dsRNA; the retinoic-acid-inducible
protein (RIG)-I and melanoma-differentiation-associated gene
(MDA) 5 and, therefore, might be potential candidates
Figure 4. A novel pathway is crucial for MAP kinases activation in poly (I:C) stimulated macrophages. A) Schematic representation of
the final TLR3 model after adding novel pathway (blue) from TRIF activates MAP kinases. B), C) and D) show simulations of NF-kB, JNK and p38
activation, respectively, of the final macrophages TLR3 model with novel pathway, in wildtype (WT) (black), TRAF6 KO (green) and TRADD KO
(orange). The x-axis represents the time in minutes and the y-axis represents the relative activation profile.
doi:10.1371/journal.pone.0004661.g004
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(I:C) [33,35] and secondly, MDA5 signaling pathway is unknown
to trigger MAP kinases [35]. Furthermore, TRIF mutation
showed abolishment of ERK activation [32] and all MAP kinases
seem to possess similar kinetics in poly (I:C) stimulation [11].
Taken together, these data suggest the predicted pathway for
JNK and p38 activation is through TRIF and not by RIG-1 or
MDA5.
Table 1. The final in silico TLR3 model reactions and parameter values.
No Reaction Formula Parameter value (1/s) Remarks
1 IM1RIM2 k1*IM1 k1=0.002 Novel intermediates acting upstream of TLR3
representing uncharacterized cellular events.
2 IM2RIM3 k2*IM2 k2=0.002
3 IM3RTLR3 k3*IM3 k3=0.002
4 TLR3RTRIF k4*TLR3 k4=0.001 TLR3 recruits TRIF.
5 TRIFRTRAF6 k5* TRIF k5=0.002 TRAF6 binds to TRIF.
6 TRIFRIM4 k6*TRIF k6=0.004 TRIF activates JNK through Novel pathway
7 TRIFRRIP1 k7*TRIF k7=0.007 RIP1 binds to TRIF.
8 TRIFRTRADD k8*TRIF k8=0.002 TRADD binds to TRIF.
9 TRIFRTRAF3 k9* TRIF k9=0. 01 TRAF3 binds to TRIF.
10 TRAF6RTAB/TAK k10*TARF6 k10=0.04 TRAF6 binds to TAB/TAK complex.
11 RIP1RIKK k11*RIP1 k11=0.04 RIP1 activated IKK complex.
12 TRADDRRIP1 k12*TRADD k12=0.0001 RIP1 ubiquitination through TRADD.
13 TRADDRMKKK k13*TRADD k13=0.04 TRADD activates JNK and p38 corresponding
MKKK.
14 MKKKRMKK3/6 k14*MKKK k14=0.04 MKKK activates JNK through activation of
MKK3/6.
15 MKKKRMKK4/7 k15*MKKK k15=0.04 MKKK activates p38 through activation of
MKK4/7.
16 TAB/TAKRMKK4/7 k16* TAB/TAK k16=0.03 Activation of MAP kinases and IKK via TAB/
TAK complex.
17 TAB/TAKRMKK3/6 k17*TAB/TAK k17=0.007
18 TAB/TAKRIKK k18* TAB/TAK k18=0.9
19 IM4RMKK3/6 k19* IM4 k19=0.04 The novel pathway activates JNK.
20 IM4RMKK4/7 k20* IM4 k20=0.04 The novel pathway activates p38.
21 IKKRNF-kB/IkB k21*IKK k21=0.00167 Phosphorylation of IkBa/NF-kB via IKK
complex.
22 IKKRp105/Tp12 k22*IKK k22=0.0009 Activation of ERK via IKK.
23 p105/Tp12RMKK1/2 k23* p105/Tp12 k23=0.003
24 NF-kB/IkBRNF-kBc k24* NF-kB/IkB k24=0.0333 Release of NF-kB after IkB phosphorylation.
25 NF-kBcRNF-kBn k25* NF-kBc k25=1.0 NF-kB translocate to the nucleus.
26 NF-kBnRNF-kBdeg k26* NF-kBn k26=0.99 NF-kB degradation.
27 MKK1/2RERKc k27*MKK1/2 k27=0.0167 Activation of ERK via MKK1/2.
28 ERKcRERKn k28* ERKc k28=0.99 ERK translocate to the nucleus.
29 ERKnRAP-1 k29* ERKn k29=0.99 ERK activates AP1.
30 MKK3/6RJNKc k30*MKK3/6 k30=0.4 Activation of JNK via MKK3/6.
31 JNKcRJNKn k31*JNKc k31=1.0 JNK translocate to the nucleus.
32 JNKnRAP-1 k32* JNKn k32=0.99 JNK activates AP1.
33 MKK4/7«p38c k33*MKK4/7 k33=0.4 Activation of p38 via MKK4/7.
34 p38cRp38n k34* p38c k34=1.0 p38 translocates to the nucleus.
35 p38nRAP-1 k35* p38n k35=0.99 p38 activates AP1.
36 AP1RAP-1deg k36* AP1 k36=0.085 AP1 degradation.
37 TRAF3RTBK1 k37*TRAF3 k37=0.0001 TRAF3-TBK1 interaction.
38 TBK1RIRF-3/7c k38*TBK1 k38=0.333 IRF3/7 binds TBK1.
39 IRF-3/7cRIRF-3/7n k39*IRF-3/7c k39=0.000167 IRF3/7 translocate to the nucleus.
40 IRF-3/7nRIRF-3/7deg k40*IRF-3/7n k40=0.0001 IRF3/7 degradation.
doi:10.1371/journal.pone.0004661.t001
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pathway, we again surveyed the literature. The TRAF family
members, six to-date, are well-known to bind to the TIR domain
of TRIF with their C-terminal [36,37,38,39], while two members
of the RIP family, RIP1 and RIP3, are found to interact with
TRIF through the RHIM domain found in RIP1, RIP3 and TRIF
[40,41]. RIP1, TRAF6 and TRAF3 already exist in the current
TLR3 signaling, while TRAF1 was recently found to inhibit the
TRIF-mediated signaling [38,39]. Thus, we suggest that RIP3,
TRAF2, TRAF4 or TRAF5 may be part of the novel pathway
activating JNK and p38.
In summary, the analysis of the poly (I:C) stimulation in
macrophages reveals the involvement of uncharacterized missing
intermediary steps prior to TLR3 activation and the existence of a
key pathway from TRIF to JNK and p38, but not NF-kB
activation. Although further experimental validation is required to
identify the uncharacterized processes and molecules nevertheless,
we show that the simple mass-action linear response can represent
activation dynamics of the TLR3 signaling, and can be used to
predict novel features of complicated immune pathways.
Materials and Methods
Development of in silico TLR3 model using perturbation-
response approach
The basic principle behind our perturbation-response approach
is to induce a controlled perturbation of a certain (input) reaction
molecule of a system, which is kept at steady-state, and monitor
the response of the concentration/activation levels of other
molecules (output) of the system. By finding a relationship between
the input perturbation (e.g. poly (I:C) stimulation) and output
response (e.g. JNK, NF-kB activation), the mechanistic properties
of the system such as network topology can be uncovered (e.g.
novel TRIF-MAP Kinases pathway) without knowing each
individual’s detailed kinetics.
To illustrate our approach, let us perturb a stable biological
network consisting of n molecules from reference (stable) steady-
state. The deterministic kinetic evolution equation is
dXi
dt
~Fi X1,X2,::,Xn ðÞ ,i~1,::,n, ð1Þ
where the corresponding vector form of Eq. 1 is dX
dt ~FX ðÞ . F is a
vector of any non-linear function of the molecules vectors X=(X1,
X2, .., Xn), which represents activated concentration levels of
signaling molecules (for example through phosphorylation,
binding concentration of transcription factors to promoter regions
etc.). The response to perturbation can be written by X=X0+dX,
where X0 is reference steady-state vector and dX is relative
response from the steady-states (dXt=0=0).
The use of small perturbation around steady-state leads to
important simplification to the evolution equation, which can be
highly non-linear (Eq. 1), resulting in the approximation of the
first-order term. In vector form, ddX
dt %
LF X ðÞ
LX
  
X~X0

dX, noting
that zeroth order term F(X0)=0 at the steady-state X0 and the
Jacobian matrix or linear stability matrix, J~
LF X ðÞ
LX
  
X~X0
. The
elements of J are chosen by fitting dX with corresponding
experimental profiles and knowing the network topology (e.g.,
activation causality). Hence, the amount of response (flux
propagated) along a signaling pathway can be determined using
the law of mass flow conservation with first order mass-action kinetics,
ddX
dt ~JdX (Table 1) [13,18,42]. We considered all signaling
response to be linear and sequential up to 90 min after poly (I:C)
stimulation (equation [2]) as apparent from the formation-
depletion activation profiles (see Experiments, and Results and
Discussion). Although there will not be any issue for parameter
sensitivity in our system because of linear events, multiple solutions
of parameter space, Js, can occur [13]. To overcome this, we
compare our (wildtype) model with two other (TRAF6 KO and
TRADD KO) experimental conditions (see Verification of Model
Parameters).
Modeling strategy
We first curated the murine macrophage TLR3 signaling
topology from current literature/database sources and by checking
with relevant experimental data (Figure 5, step 1 and see Results
and Discussion) [11,12,31,24,40,41,43]. Next, using the topology,
we developed a dynamic model of TLR3 signaling on the E-Cell
simulation platform [44] to simulate the dynamics of NF-kB and
JNK activation (Figure 5, step 2). The parameters of our model
(elements of Jacobian matrix J) were estimated by fitting the
simulation profiles of NF-kB, JNK and p38 with corresponding
activation profiles semi-quantified from immunoblots, obtained
from wildtype macrophages [11] (Figure 5, step 3) (Note that our
model works quantitatively if appropriate data is available). If the
model successfully fits the wildtype profile of NF-kB and JNK, we
accept the model and call it the Reference Model (Figure 5, step
4). Otherwise, if the model fails, we adjust the parameters values or
model topology until the model is able to simultaneously fit the
experimental profiles of NF-kB, JNK and p38 reasonably
(Figure 5, step 5).
The model simulation results were deemed acceptable by
comparing the simulation profile with the experimentally semi-
quantitative profile based on three criteria; i) time of activation
onset, ii) time to reach peak, and iii) decay profile (Figure 5 insert).
For example, JNK experimental profile shows null activation until
10 min, peak activation at 30 min and decaying trend until
90 min (Figure 1B, WT). In our first simulation of JNK (Figure 2C,
WT), the time of activation onset was almost instantaneous, peak
at around 10 min, and complete decay after 60 min. This
simulation, therefore, is considered BAD based on the three
criteria which poorly matched (Figure 5 insert, upper panel). On
the other hand, after modifying the signaling topology by adding
novel intermediary steps, the simulation improved on all three
criteria and considered GOOD (Figure 3C, WT, and Figure 5
insert, lower panel).
Verification of Model Parameters
There can be several parameter spaces for Jacobian matrix, Js,
which could fit wildtype semi-quantitative activation profiles of
NF-kB, JNK and p38. To reduce the parameter spaces, we
performed an iterative two-mode process of model ‘‘creation’’ and
‘‘testing’’; ‘‘Creation’’ is to develop and fit our model with
published available semi-quantitative profiles of NF-kB and MAP
kinases activity in wildtype (step 4). ‘‘Testing’’ is to optimize
reaction networks and parameter values, obtained from step 4, by
simulating the knockout (KO) conditions (TRAF6 KO and
TRADD KO) and comparing the results with their respective
experimental profiles of NF-kB and MAP kinases activation
[11,12]. Each KO model was generated from the wildtype model
by setting the parameters involving the KO molecule null. If our
KO simulation does not compare well with experiments, we re-
tune the model parameters till the model simulations fit the
activation profiles of both wildtype and TRAF6 KO (Figure 5 step
6). If unsuccessful, we modify the topology so that a better fit can
Rewiring the TLR3 Signaling
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doi:10.1371/journal.pone.0004661.g005
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PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4661be obtained, for example, adding novel signaling intermediates to
obtain the delayed activation [17] or crosstalk mechanism to
provide an alternative source of activation in the KO condition
[42,45,46] (Figure 5 step 4, see Results and Discussion). To avoid
false prediction, we further check comparing the model simulation
against TRADD KO. When the model fails at these steps, it
implies that either J (parameter space) is not correct or the
represented topology is insufficient. We repeat the procedure of
modifying parameter values and topology until we obtained
reasonable predictions for all 3 conditions (wildtype, TRAF6 KO
and TRADD KO) at 6 time points (0, 10, 20, 30, 60 and 90 min).
At this point, we accepted the model and called it the Robust
Model (Figure 5 step 7). Therefore, using steps 1–7, we were able
to identify missing or incorrect feature(s) of the TLR3 pathways.
The final (robust) TLR3 model’s equations and parameter values
can be found in Table 1.
Final TLR3 Response Model
Our final model consists of 34 molecules with 40 reactions and
parameters developed after comparing with dynamics of 3
molecules (NF-kB, JNK and p38) at 6 time points (0, 10, 20, 30,
60 and 90 min) for 3 conditions (wildtype, TRAF6 KO and
TRADD KO) (Table 1).
Experiments on macrophages
We utilized our published time-course experimental data of NF-
kB, JNK and p38 of wildtype (model creation) and TRAF6-
deficient (model testing) macrophages with 10 mg/ml poly (I:C)
stimulation [11]. For further model testing, we utilized published
experimental profile of NF-kB, JNK and p38 of TRADD-deficient
macrophages with similar poly (I:C) stimulation [12]. The
activation levels of NF-kB, JNK and p38 (Figure 1A–B, Figure
S1A) were quantified from the western blots using ImageJ (http://
rsbweb.nih.gov/ij/).
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